Sarbanes Connects the Dots Between High Prescription Drug Prices and Big Pharma’s Influence Peddling in Washington [Video]
FOR IMMEDIATE RELEASE
WASHINGTON, D.C. – At a House Committee on Oversight and Reform hearing today, Democracy Reform Task Force Chair Rep. John Sarbanes (D-Md.) explained how record-breaking campaign donations and lobbying efforts have stymied Congressional action to lower prescription drug prices.
“One of the reasons why it’s difficult to [lower prescription drug prices] is because these industries have a lot of influence on how policy get made, and when they see these changes coming down the road they rev up that influence machine and it has an impact,” said Congressman Sarbanes. “According to the Center for Responsive Politics, the pharmaceutical industry spent more on lobbying than any other industry last year – $280 million. In the 2018 election cycle, the industry donated over $41 million to federal candidates and committees. Big Phrama had over 1,400 lobbyists last year. That’s three lobbyists for each Member of the House.”
Sarbanes continued: “When we go to try and fix the law, that influence gets in the way and the money gets in the way. And I think many of our constituents would say that too often Congress is leaning in the direction of the big money and the special interests and away from the interest of the broad public.”
To fight back against the undue influence of Big Pharma and other wealthy and well-connected industries, Congressman Sarbanes authored and introduced H.R. 1, the For the People Act – a once-in-a-generation package of reforms that will end the dominance of big money in politics, rein in lobbyists, clean up the culture of corruption in Washington and put the American people back in charge of our democracy.
See below for the full video of the Congressman’s remarks.
See here for more information about H.R. 1, the For the People Act.